Ocrevus Zunovo

The dosage of Hyaluronidase (human Recombinant) is highly dependent on the specific clinical application and the other medications being administered.

• For Hypodermoclysis (Subcutaneous Hydration): The standard dose is typically 150 USP units added to the injection site before or during the administration of 1,000 mL or more of subcutaneous fluid. Your healthcare provider will adjust the rate of fluid administration based on your age, weight, and clinical response.
• For Absorption of Injected Drugs: Typically, 150 USP units are mixed with the medication or injected into the site immediately prior to the medication. In local anesthesia, doses may range from 15 USP units to 150 USP units depending on the volume of the anesthetic.
• In Oncology (Co-formulations): When used as part of a combination product (like Darzalex Faspro), the dose of hyaluronidase is fixed within the formulation (e.g., 2,000 units per mL or higher) and is administered according to the specific oncology protocol.

Hyaluronidase (human Recombinant) is FDA-approved for use in pediatric patients, particularly for hypodermoclysis.

• Fluid Administration: The dose is generally 150 USP units. However, special care must be taken in children under the age of 3. In these patients, the volume of subcutaneous fluid should be limited to 200 mL per injection site to prevent excessive localized pressure and tissue damage.
• Premature Infants/Neonates: Use in very small infants requires extreme caution and precise fluid monitoring. Your pediatrician will determine the exact volume based on the infant's weight and electrolyte status.

Renal Impairment

No specific dosage adjustments are required for patients with kidney disease, as the enzyme is metabolized proteolytically and not primarily cleared by the kidneys. However, the fluids being dispersed by the enzyme (such as saline or medications) may require adjustment.

Hepatic Impairment

There are no known requirements for dosage adjustments in patients with liver impairment. The metabolic pathway of recombinant proteins does not typically rely on hepatic CYP450 function.

Elderly Patients

Older adults are more prone to skin fragility and may have different fluid requirements. While the dose of hyaluronidase remains the same (150 units), healthcare providers must monitor the injection site closely for signs of over-hydration or skin breakdown.

This medication is administered exclusively by healthcare professionals via subcutaneous (under the skin) injection. It is never self-administered by the patient at home unless as part of a pre-filled, co-formulated biologic pen under strict medical supervision.

• Preparation: The solution should be clear and colorless. If it is discolored or contains particles, it should not be used.
• Site Selection: The injection is usually given in the abdomen, thigh, or upper arm. The site should be rotated if multiple injections are required.
• Storage: Most recombinant hyaluronidase products must be stored in a refrigerator (2°C to 8°C or 36°F to 46°F) and protected from light. Do not freeze.

Because this medication is typically administered in a clinical setting by a nurse or doctor, a missed dose is unlikely. If you miss a scheduled appointment for an injection that includes hyaluronidase (such as a cancer treatment), contact your oncology clinic immediately to reschedule. The timing of these doses is often critical for the effectiveness of the primary medication.

An overdose of Hyaluronidase (human Recombinant) is rare but may lead to local reactions. Symptoms of an excessive dose include:

• Significant redness (erythema) at the site
• Swelling or hives (urticaria)
• Dizziness or low blood pressure

In the event of a suspected overdose, the injection should be stopped immediately. Treatment is supportive, often involving antihistamines or corticosteroids if an allergic reaction occurs.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to administer this medication yourself without explicit medical guidance and training.

The most frequently reported side effects of Hyaluronidase (human Recombinant) are localized to the area where the injection was given. Because the enzyme opens up the tissue, some reaction is expected as the body adjusts to the rapid influx of fluid or medication.

• Injection Site Pain: A sharp or stinging sensation during the injection, which usually fades within minutes.
• Erythema (Redness): The skin at the site may appear flushed or red. This is typically due to increased blood flow to the area and the enzymatic activity.
• Edema (Swelling): Because the enzyme allows more fluid into the subcutaneous space, the area may look swollen or puffy for several hours.
• Itching (Pruritus): A mild itchy sensation at the site is common and usually does not indicate a full-blown allergy.

• Induration: The skin at the injection site may feel firm or hard to the touch for a day or two.
• Bruising: Small amounts of bleeding under the skin (ecchymosis) can occur at the needle entry point.
• Rash: A localized rash that stays within a few centimeters of the injection site.

• Anaphylactoid Reactions: While much rarer with recombinant human forms than animal-derived forms, some patients may experience severe allergic reactions including difficulty breathing, swelling of the face/lips, and a rapid drop in blood pressure.
• Antibody Formation: In rare cases, the body may develop antibodies against the enzyme. While this rarely causes symptoms, it could theoretically make future doses less effective.

> Warning: Stop taking Hyaluronidase (human Recombinant) and call your doctor immediately if you experience any of these.

• Anaphylaxis: Signs include hives, swelling of the throat, wheezing, or feeling like you might pass out. This is a medical emergency.
• Severe Local Inflammation: If the injection site becomes extremely hot, painful, or develops blisters, this may indicate a skin infection or a severe tissue reaction.
• Systemic Toxicity: If hyaluronidase is accidentally injected into a vein along with other medications (like local anesthetics), it can cause the other drugs to enter the bloodstream too quickly, leading to heart or central nervous system issues.
• Spreading of Pre-existing Infection: If injected into an area that already has an infection, the enzyme can cause the infection to spread rapidly to surrounding tissues (cellulitis).

Hyaluronidase (human Recombinant) is typically used for short-term procedures or intermittent oncology treatments. There are no well-documented long-term side effects related to the enzyme itself, as it is rapidly broken down and the skin's hyaluronan is replenished within 48 hours. However, repeated injections at the same site over many years (as in chronic immunoglobulin therapy) may lead to localized changes in skin texture or localized scarring (lipohypertrophy), though this is more often related to the primary medication than the hyaluronidase.

As of 2026, there are no FDA black box warnings specifically for Hyaluronidase (human Recombinant) as a standalone agent (e.g., Hylenex). However, when it is co-formulated with other drugs (like Rituximab or Trastuzumab), the product label will contain the black box warnings associated with those specific primary drugs (e.g., infusion reactions, embryo-fetal toxicity, or cardiac toxicity). Always review the full prescribing information for the specific combination product you are receiving.

Report any unusual symptoms to your healthcare provider. Even mild side effects should be noted so your care team can adjust your administration technique or provide pre-medications like antihistamines if necessary.

Hyaluronidase (human Recombinant) is generally well-tolerated, but its unique mechanism as a 'spreading factor' carries specific risks. Because it increases tissue permeability, it can inadvertently spread substances that should remain localized. It should never be injected into or around an area that is infected or acutely inflamed, as this may facilitate the spread of the infection (e.g., cellulitis). Additionally, it should not be used to enhance the absorption of dopamine or other alpha-agonist medications, as this can lead to severe local tissue death (necrosis).

No FDA black box warnings for Hyaluronidase (human Recombinant) as a standalone agent. However, patients receiving combination products (such as Darzalex Faspro or Phesgo) must be aware of the black box warnings for the associated monoclonal antibodies, which may include risks of severe infusion-related reactions or heart failure.

• Allergic Reactions / Anaphylaxis Risk: Although the recombinant human form has a lower risk of allergy than animal-derived enzymes, hypersensitivity can still occur. A 'skin test' for sensitivity is sometimes performed before the first dose if the patient has a history of severe allergies to proteins. If you experience itching, hives, or shortness of breath, notify your nurse immediately.
• Spreading of Malignancy: There has been historical theoretical concern that hyaluronidase could facilitate the spread (metastasis) of cancer cells if injected directly into a tumor. Therefore, it is generally not injected into or through a known cancerous mass, except when used as a specific part of an approved oncology protocol.
• Extravasation Management: While hyaluronidase is sometimes used off-label to treat the leakage of certain IV drugs into the skin (extravasation), it should NOT be used for all drugs. For example, it should not be used for 'vinca alkaloid' chemotherapy leaks without specific specialist guidance.
• Fluid Overload: In patients receiving hypodermoclysis (subcutaneous fluids), there is a risk of fluid overload, especially in patients with congestive heart failure or advanced kidney disease. Healthcare providers will monitor for signs such as shortness of breath or rapid weight gain.

Patients receiving Hyaluronidase (human Recombinant) do not typically require specific blood tests for the enzyme itself. However, monitoring is required for the primary treatment:

• Injection Site Monitoring: Nurses will check the site for excessive redness, swelling, or signs of infection.
• Vital Signs: Blood pressure and heart rate are often monitored during and after the injection to check for allergic reactions.
• Hydration Status: For those receiving fluids, electrolyte levels (sodium, potassium) and kidney function (creatinine) may be checked periodically.

Hyaluronidase (human Recombinant) itself does not typically cause drowsiness or cognitive impairment. However, it is often administered alongside other medications (like pain relievers or chemotherapy) that can affect your ability to drive. Do not operate heavy machinery until you know how the entire combination of medications affects you.

There are no known direct interactions between alcohol and Hyaluronidase (human Recombinant). However, alcohol can cause dehydration or affect the way your body processes other medications being given with the enzyme. Discuss your alcohol consumption with your doctor, especially if you are undergoing cancer treatment.

Since this drug is usually given for a specific procedure or as part of a scheduled treatment cycle, there is no 'withdrawal' or need for tapering. However, if you stop receiving the hyaluronidase component of a subcutaneous oncology drug, you may have to switch back to much longer intravenous infusions, which carries different risks and logistical challenges.

> Important: Discuss all your medical conditions, especially any history of heart failure, kidney disease, or severe allergies, with your healthcare provider before starting Hyaluronidase (human Recombinant).

• Dopamine and Alpha-Agonists: Hyaluronidase (human Recombinant) should not be used to enhance the absorption of dopamine or alpha-adrenergic receptor agonists. The clinical consequence is an increased risk of local tissue necrosis (death of skin cells) because the enzyme spreads these potent vasoconstrictors too widely, cutting off blood supply to the area.
• Local Anesthetics in Infected Areas: Do not use hyaluronidase to spread local anesthetics into an area that is already infected (e.g., an abscess), as this can push the bacteria deeper into the bloodstream or surrounding healthy tissue.

• Furosemide (Lasix): When added to the same injection solution, furosemide has been reported to be physically incompatible with hyaluronidase, causing the solution to become cloudy or form a precipitate. They should be administered through separate sites.
• Phenytoin: Similar to furosemide, phenytoin is chemically incompatible with hyaluronidase in the same syringe or IV line.
• Corticosteroids: Drugs like dexamethasone or hydrocortisone, when used in high doses locally, may slightly reduce the effectiveness of hyaluronidase by stabilizing the tissue matrix, though they are often used together in clinical practice without major issues.

• Local Anesthetics (e.g., Lidocaine): While hyaluronidase is used to enhance the spread of anesthetics, it also speeds up their removal from the site. This means the numbing effect may start faster but wear off sooner. Your doctor may need to adjust the dose of the anesthetic to maintain the desired effect duration.
• Salicylates (Aspirin): High doses of salicylates may theoretically inhibit the enzyme's activity slightly, though this is rarely clinically significant for most patients.
• Antihistamines: These can sometimes reduce the 'spreading' effect of hyaluronidase because they stabilize the capillaries and tissue membranes.

There are no known interactions between Hyaluronidase (human Recombinant) and specific foods, including grapefruit, dairy, or high-fat meals. Because the drug is injected subcutaneously and bypasses the digestive system, food intake does not affect its absorption or metabolism.

• Vitamin C (Ascorbic Acid): Large doses of Vitamin C may theoretically interfere with the breakdown of hyaluronan, potentially reducing the enzyme's efficacy, though this has not been proven in human clinical trials.
• St. John's Wort: While it affects many drugs via the liver, it does not interact with hyaluronidase because the enzyme is not metabolized by the liver's CYP450 system.

Hyaluronidase (human Recombinant) is not known to interfere with standard laboratory tests, such as blood glucose, liver enzymes, or kidney function panels. However, it can affect the results of 'skin tests' for allergies. If you are undergoing allergy testing, inform your allergist if you have recently received hyaluronidase, as it may cause a 'false positive' spreading of the allergen, making it difficult to interpret the test results.

For each major interaction, the primary mechanism is either physical incompatibility (the drugs clump together in the syringe) or pharmacodynamic (the enzyme changes how fast the other drug works or is removed). Management typically involves using separate injection sites or adjusting the timing of the doses.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including any creams or ointments you apply to the skin near the injection site.

Hyaluronidase (human Recombinant) must NEVER be used in the following circumstances:

• Hypersensitivity: Any patient with a known, documented severe allergy or anaphylactic history to Hyaluronidase (human Recombinant) or any of the inactive ingredients (such as human albumin or thimerosal in some older formulations) must not receive this drug. Re-exposure can lead to life-threatening anaphylaxis.
• Injection into Infected Areas: It is absolutely contraindicated to inject the enzyme into or through an area of cellulitis, an abscess, or any localized infection. The mechanism of action (increasing tissue permeability) would allow the bacteria or toxins to spread rapidly into the systemic circulation, potentially causing sepsis.
• Direct Venous Injection: While some medications are given IV, the standalone hyaluronidase enzyme is intended for subcutaneous or interstitial use. It should not be injected directly into a vein, as it is rapidly inactivated by the blood and will not provide the intended local 'spreading' effect.

Conditions requiring careful risk-benefit analysis by a healthcare provider:

• Malignancy at the Site: Unless part of a specific oncology treatment plan, doctors avoid injecting hyaluronidase near a tumor due to the theoretical risk of facilitating the movement of cancer cells into the lymphatic system.
• Congestive Heart Failure (CHF): In patients receiving large volumes of fluid via hypodermoclysis, the increased absorption rate facilitated by hyaluronidase can put a sudden strain on a weak heart, potentially leading to pulmonary edema (fluid in the lungs).
• Severe Renal Impairment: While the enzyme is safe, the fluids or drugs it helps absorb may accumulate to toxic levels if the kidneys cannot clear them.

Patients who have had allergic reactions to animal-derived hyaluronidase (bovine or ovine) may be able to tolerate the recombinant human form, but they must be monitored with extreme caution. There is a lower risk of cross-reactivity because the recombinant version lacks the foreign animal proteins, but the enzymatic structure itself could still be a trigger for highly sensitive individuals.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of skin infections or heart problems, before prescribing Hyaluronidase (human Recombinant).

Hyaluronidase (human Recombinant) is classified as Pregnancy Category C (under the older FDA system). There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with the recombinant human form specifically to determine its effects on the fetus.

• Trimester-Specific Risks: It is generally avoided during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus.
• Labor and Delivery: It is sometimes used during labor to enhance the effect of local anesthetics (like an epidural or pudendal block). In these cases, it is used in very small amounts and is not known to cause harm to the newborn.
• Fertility: There is no data suggesting that hyaluronidase affects human fertility.

It is not known whether Hyaluronidase (human Recombinant) is excreted in human milk. However, because the enzyme has an extremely short half-life in the blood (minutes) and is a large protein molecule that would likely be digested in the infant's stomach if any were present in milk, the risk to a nursing infant is considered very low. Many clinicians consider it compatible with breastfeeding, but a risk-benefit discussion is recommended.

Hyaluronidase (human Recombinant) is frequently used in pediatric medicine, primarily for subcutaneous rehydration (hypodermoclysis) when IV access is difficult to maintain.

• Approved Age Ranges: It is used in infants, children, and adolescents.
• Special Considerations: In children under 3 years old, the volume of fluid given at any one site must be carefully controlled (usually not exceeding 200 mL) to prevent tissue damage from excessive pressure.
• Safety: Clinical trials have shown it to be safe and effective for fluid management in children with mild to moderate dehydration.

In the elderly, Hyaluronidase (human Recombinant) is a vital tool for preventing dehydration.

• Skin Fragility: Older patients often have thinner, more fragile skin. Healthcare providers must be careful not to inject fluids too quickly, even with the enzyme, to avoid skin tears.
• Polypharmacy: While the enzyme doesn't interact with many drugs, elderly patients are often on multiple medications (like blood thinners) that could increase the risk of bruising at the injection site.
• Heart Health: Close monitoring for fluid overload is essential in the geriatric population.

No dosage adjustment of Hyaluronidase (human Recombinant) is necessary for patients with renal impairment. However, if the enzyme is being used to facilitate the absorption of a drug that is cleared by the kidneys (like certain antibiotics), that primary drug's dose must be adjusted based on the patient's Glomerular Filtration Rate (GFR).

There are no specific guidelines for hepatic impairment. The enzyme is broken down by general body proteases rather than liver-specific enzymes, making it safe for use in patients with liver disease from a pharmacokinetic standpoint.

> Important: Special populations require individualized medical assessment to ensure that the increased rate of drug absorption does not lead to systemic complications.

Hyaluronidase (human Recombinant) is a soluble endoglycosidase. Its molecular target is hyaluronan (hyaluronic acid), a high-molecular-weight polysaccharide that forms the structural backbone of the extracellular matrix in the skin and connective tissues. Hyaluronan consists of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine.

The enzyme works by hydrolyzing the β-1,4-glycosidic bonds within these hyaluronan chains. This chemical cleavage breaks the long, viscous molecules into smaller, less viscous fragments. This process results in a temporary decrease in the viscosity of the 'interstitial cement,' which increases the permeability of the tissue. This allows injected fluids and large-molecule drugs (like monoclonal antibodies) to flow more freely through the tissue and reach the lymphatic and blood capillaries for systemic absorption.

• Onset of Action: The effect on tissue permeability is virtually immediate upon injection.
• Duration of Effect: The 'spreading' effect typically lasts between 24 and 48 hours. This is the time it takes for the body's fibroblasts to resynthesize new hyaluronan and restore the normal integrity of the extracellular matrix.
• Dose-Response: There is a clear relationship between the dose of hyaluronidase and the area of dispersion, up to a plateau point. Standard doses of 150 units are generally sufficient to facilitate the absorption of 1,000 mL of fluid.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Local tissue effect) |

| Protein Binding | Minimal (Acts as an enzyme, not a bound ligand) |

| Half-life | 2 to 5 minutes (Systemic) |

| Tmax | Immediate (Local effect) |

| Metabolism | Proteolysis (Broken down into amino acids) |

| Excretion | Not excreted intact; metabolized by proteases |

• Molecular Formula: C2555H3918N688O755S24 (Approximate for the protein component)
• Molecular Weight: Approximately 61,000 Daltons (61 kDa).
• Solubility: Highly soluble in water and physiological saline solutions.
• Structure: It is a highly purified glycoprotein consisting of 447 amino acids. It is produced by recombinant DNA technology using a mammalian cell line (CHO cells), ensuring the glycosylation pattern matches human physiology.

Hyaluronidase (human Recombinant) is classified as an Endoglycosidase and a Dispersion Enhancer. It is the key component of the ENHANZE® drug delivery technology. It is related to animal-derived hyaluronidases (Amphadase, Vitrase) but is distinguished by its recombinant human origin, which offers higher purity and lower immunogenic potential.